Drugs Go From Hit to Dud in $15 Billion Hepatitis Race: Health
This article is for subscribers only.
Jean-Michel Pawlotsky has déjà vu.
The doctor in the town of Creteil, just outside Paris, is telling hepatitis C patients to delay treatment until later this year, when two new drugs that may boost their chances of defeating the lethal liver infection hit the market.